EUROpean network of transnational collaborative RTD projects in the field of NANOMEDicine 1 www.euronanomed.net What are the societal needs? - the challenge for Europe Improve public health and welfare – Ageing population – Efficiency of current medical solutions – Emergence of new disease and old diseases are back – Personalized medicine future directions www.euronanomed.net 2 The global challenge • Therapeutic solutions for only 1/3 known diseases (WHO) • Infections: HIV, TB, malaria, risk of pandemia • Need to increase capability and innovation of medical industry – Rapid and accurate diagnosis for early detection, even prevention – Novel, more efficient therapies with less side effects www.euronanomed.net 3 Nano from research to patient and industry Nanomedicine: the application of nanotechnology to achieve breakthroughs in healthcare Foto: kaibara87/www.flickr.com www.euronanomed.net 4 Principle of the ERA-net scheme ES G UK F CP DE CP CP With ERA-Net CP CP Without ERA-Net Prog Prog F G Prog Prog UK ES Prog DE … (CP: Call for projects) Common transnational dedicated CP € : EC supports the coordination costs. Each national programme supports their national partners within the selected projects www.euronanomed.net 5 Who we are 24 partners (agencies and ministries) from 18 countries/regions Aligning parts of their national / regional funding programs according to the FP7 ERA-Net scheme Started January 2009 for 3 years EU funding for coordination (FP7) 3 common joint calls for proposals 2009, 2010, 2011 Joint trans-national RTD projects in nanomedicine EuroNanoMed achieves a critical mass of actors www.euronanomed.net 6 EuroNanoMed: an asset to bridge the gap Aims of the Calls Develop innovative diagnostic and therapeutic solutions for the patient Solving unmet medical needs Enhancing the competitiveness of the European health industry Maturation of the Nanomedicine field in Europe Cross-border collaboration between the best researchers / teams in Nanomedicine, bringing together teams from academic / public research clinical / public health industry www.euronanomed.net 7 Why now? What’s the urgency? • Health industry: a key for future growth • European countries invest substantially in nano industry and basic nano research • Nano technologies: a promising field for innovation and patient application Despite these efforts, Europe is lagging behind the US in an increasing competition : Europe needs to act now! www.euronanomed.net 8 Expected outcome • To move innovation from knowledge to industrial technology and health care applications • Opening the national programmes to support transnational RTD partnerships Long term vision: formula for an Europeanwide integrated programme with a coordinated funding www.euronanomed.net 9 Contacts • Coordinator and Executive Board Chair Dr. Virginie Sivan Commissariat à l’Energie Atomique (CEA) Virginie.sivan@cea.fr (+33) 1 69 08 87 99 • Network Steering Committee chair Dr. Olaf Rotthaus VDI Technologiezentrum GmbH (VDI) rotthaus@vdi.de (+49) 211 6214-233 www.euronanomed.net 10 Joint Transnational Calls for proposals : RESULTS JTC-1: 2009 JTC-2: 2010 www.euronanomed.net 11 RESULTS JTC-1 and JTC-2 Submitted projects JTC-1 2009 24 JTC-2 2010 33 Partners 117 178 Country/region 19 19 Funded projects 8 8 Partners 40 46 Country/region 14 10 Success rate 33% 24% Total costs (M€) 16.9 15.9 Requested budget (M€) 9.4 9 www.euronanomed.net 12 Fr an Ge ce rm an Sw y ed en S Sw pai n it z Th e e r la Ne nd th er lan ds Isr Ita ae ly l P (V or en tu et ga o l Re gi o Ro n) ma nia Ita ly (N PC ) Po Ba lan sq d ue Lit hu Re an gi ia on (S pa in) Tu rk ey UK W De a ll ( oo nm NP C) n ar Re k( g io NP n C) (B elg ium ) La tv Hu ia ng Ire ar lan y d Be (N lgi PC um ) (N PC ) Submitted projects Partners distribution /country-region JTC-1 www.euronanomed.net JTC-2 40 35 30 25 20 15 10 5 0 13 Submitted projects Category of partners JTC-1 2009 JTC-2 2010 Consortium composition Translational Academia / public Academia research collaboration 12% 18% 12% Industry Industry 25% Clinic / public Clinical / public health 57% 22% 66% health 66% Translational collaboration 22% 48% 52% Translational Collaboration Three categories 48% 52% Three categories 39% Two categories (required) www.euronanomed.net 61% 14 Three categories 1% Submitted projects Main scientific subfields JTC-1 2009 JTC-2 2010 4; 17% 4; 17% 5; 21% 15; 62% 15; 62% Targeted delivery system Targeted delivery system Regenerative medicine Regenerative medicine Diagnostic Diagnostic 9; 27% 17; 52% 7; 21% www.euronanomed.net 15 Funded projects Partners /country-region JTC-1 2009 France Spain Germany Sweden Switzerland The Netherlands Denmark (NPC) Island Italy (NPC) Veneto Region Lithuania Poland Portugal Basque Region JTC-2 2010 8 8 7 4 3 2 1 1 1 1 1 1 1 1 France 10 Germany 9 Sweden 6 Portugal 5 Switzerland 5 Spain 5 Romania 3 Poland 1 Turkey 1 Latvia 1 Total 46 Total 40 www.euronanomed.net 16 1% Funded projects Main scientific subfields JTC-1 2009 4; 17% 3 515; 62% JTC-2 2010 Targeted delivery system Targeted delivery system Regenerative medicine Regenerative Diagnostic medicine Targeted delivery system Regenera medicine 2 1 5 Diagnost -gene therapy -Immunotherapy -photodynamic therapy -anti-cancer therapies -development of vaccines -regeneration of the nervous system and sensory organs. www.euronanomed.net -cancer -inflammatory diseases -bone regeneration -muscular dystrophy -immunology -vaccines 17 EuroNanoMed: open Call 3rd Joint Transnational Call for Proposals 14 Countries / Regions Deadline: April 15th 2011 www.euronanomed.net 18 Participating Funding Organisations Industry, Innovation, Trade and Tourism Department, Basque Government The French National Research Agency (ANR) VDI Technologiezentrum GmbH The Icelandic Centre for Research (RANNIS) The Chief Scientist Office, The Ministry of Health (CSO-MOH) The Latvian Academy of Sciences (LAS) Science Council of Lithuania (LSC) National Centre for Research and Development (NCBiR) Unitatea Executiva pentru Finantarea Invatamantului Superior, a Cercetarii, Dezvoltarii si Inovarii (UEFISCDI) Instituto de Salud Carlos III (ISCIII) Swiss National Science Foundation (SNSF) The Scientific and Technological Research Council of Turkey (TUBITAK) Project Unit research and innovation, Veneto Region Ministry of the Walloon Region: Operational General Directorate for Economy, Employment,and Research (DGOEER) www.euronanomed.net BASQUE REGION (SPAIN) FRANCE GERMANY ICELAND ISRAEL LATVIA LITHUANIA POLAND ROMANIA SPAIN SWITZERLAND TURKEY VENETO REGION (ITALY) WALLOON REGION (BELGIUM) 19 Topics / Funding Topics Diagnostics Targeted drug delivery Regenerative medicine Funding Indicative total funding 11 M € Duration: Up to 3 years Every project partner will receive the funding from his national agency www.euronanomed.net 20 Eligibility criteria Consortium composition 3 – 7 partners per consortium Partners from at least 3 different countries (with a majority of partners from funding member states/regions participating in the call) Partners from at least two of the three categories academic / public research clinical / public health industry Eligibility of partners also depends on national regulation in their country or region! Read carefully the “Country specific information for applicants” Contact your national agency (contact person) www.euronanomed.net 21 Time lines Call open since: January 14th 2011 Deadline for proposals: April 15th 2010, 17:00:00 (Brussels Time) Funding Decision: October 2011 Start of Projects: January 2012 www.euronanomed.net 22 How to apply? 1. EuroNanoMed Website www.euronanomed.net www.euronanomed.net 23 How to apply? 2. Download Call Text , Guidelines for applicants and Country specific Information www.euronanomed.net 24 How to apply? 3. Contact your national contact point (list in the Country-region specific information) 4. Download and fill in the Proposal Template www.euronanomed.net 25 How to apply? 5. Online Submission using the EuroNanoMed Submission Tool www.nanomedsubmission.net www.euronanomed.net 26 How to apply? Register by clicking on the link ”to register” on the homepage http://www.euronanomed.net/*; you will receive an email confirming your registration Accede to the EuroNanoMed Electronic Submission System* (Use the username and password you chose for the registration) fill in all the details and upload your proposal document (pdf format only), which you have previously filled in on your computer (see The Proposal Template)*. Submit your proposal : Click on “submit proposal” to confirm your submission; you will receive an email confirming its receipt. Modify your data at any time until the submission deadline. It is strongly recommended to transfer the final version in proper time before this date www.euronanomed.net 27 Expression of Interest Tool Present your project ideas Find partners www.nanomedsubmission.net www.euronanomed.net 28 For more information EuroNanoMed Call Office Veneto Nanotech s.c.p.a. Via San Crispino, 106 35129 Padova – Italy : +39 049 7705520 e-mail: calloffice@euronanomed.net National / Regional Contact Points www.euronanomed.net www.euronanomed.net 29 Together we are building Nanomedicine for the future! 30 www.euronanomed.net